Trial Profile

A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Trastuzumab (Primary) ; Carboplatin; Docetaxel
Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms TCHL-Phase-II

Most Recent Events

05 Jun 2025 Results of 5-year follow-up with serum biomarker analysis were published in the Acta Oncologica.
01 Jun 2021 Results performing tumour-associated lymphocytes analysis and T-cell analysis by immunohistochemistry on the pretreatment and on-treatment samples from NCT01485926, published in the Breast Cancer Research and Treatment
29 Oct 2020 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com